Sanofi discontinues Nurix's Phase 1 STAT6 degrader SAR448272

What's the deal? On 3 November 2026, Sanofi notified Nurix Therapeutics that it will discontinue the Phase 1 first-in-human trial of SAR448272, an oral STAT6 degrader, and terminate the programme. As a result, Nurix does not expect to receive any of the future development, regulatory or commercial milestone payments and royalties tied to SAR448272 under its collaboration with Sanofi.

Why it matters: Targeted protein degradation is a newer drug-discovery approach in which small molecules are designed to mark disease-causing proteins for destruction by the cell's own recycling machinery, rather than simply blocking them. SAR448272 was one of two transcription-factor programmes Sanofi licensed from Nurix in 2025 under an extended 2019 collaboration, which uses Nurix's DEL-AI discovery platform. Nurix retains the option to co-develop and co-promote both programmes in the United States; the second, undisclosed target is unaffected by today's announcement.

Nurix says its other partnered and wholly owned programmes continue unchanged, including bexobrutideg (a BTK degrader in Phase 3 with Roche), NX-1607 (a CBL-B inhibitor in Phase 1b) and an IRAK4 degrader in Phase 1 with Gilead. The company holds approximately $1.1 billion in cash and expects to fund operations into the second half of 2029.

Read more: Nurix Therapeutics, 03 November 2026 · Fierce Biotech, 04 November 2026